688276.SHG Changchun BCHT Biotechnology Co. A
- Market cap
- CNY 6.65B
- P/E
- -
- P/B
- 1.70x
- ROE
- -2.7%
- Dividend yield
- 1.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688276.SHG undervalued?
Graham numberThe Graham number of Changchun BCHT Biotechnology Co. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Changchun BCHT Biotechnology Co. A fundamental analysis
No fundamental analysis for Changchun BCHT Biotechnology Co. A yet.
Changchun BCHT Biotechnology Co. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Changchun BCHT Biotechnology Co. A
Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. It offers therapeutic biological products; general cargo road transport; special cargo transport and import and export of goods and technology. The company's products Varicella vaccine, nasal spray flu vaccine, herpes zoster vaccine, liquid nasal spray flu vaccine. Changchun BCHT Biotechnology Co. Lt…
Full company profileChangchun BCHT Biotechnology Co. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Changchun BCHT Biotechnology Co. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 691M | 1.02B | 976M | 1.44B | 1.20B | 1.07B | 1.82B | 1.23B | 592M | 609M |
| Gross Profit | 614M | 900M | 873M | 1.27B | 973M | 890M | 1.61B | 1.02B | 592M | 478M |
| Operating Income | 114M | 149M | 268M | 482M | 262M | 187M | 559M | 258M | -363M | -80.0M |
| EBITDA | 140M | 191M | 315M | 550M | 330M | 269M | 657M | 362M | -239M | -123M |
| Net Income | 93.5M | 128M | 221M | 418M | 244M | 182M | 501M | 232M | -272M | -104M |
| EPS | 0.26 | 0.36 | 0.61 | 1.14 | 0.62 | 0.44 | 1.21 | 0.56 | -0.66 | -0.25 |
| Balance Sheet | ||||||||||
| Total Assets | 1.14B | 1.41B | 1.58B | 2.47B | 4.17B | 4.28B | 5.05B | 5.20B | 5.07B | 5.13B |
| Total Liabilities | 542M | 611M | 570M | 688M | 757M | 724M | 1.03B | 987M | 1.22B | 1.34B |
| Shareholders' Equity | 601M | 800M | 1.01B | 1.78B | 3.42B | 3.56B | 4.02B | 4.22B | 3.85B | 3.79B |
| Cash & Short-term Investments | 129M | 210M | 273M | 310M | 1.16B | 867M | 442M | 345M | 201M | 285M |
| Total Debt | - | 165M | 165M | - | - | - | 20.5M | 103M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 177M | 270M | 233M | 209M | 140M | 39.8M | 255M | 407M | 231M | - |
| Capital Expenditure | 92.4M | 181M | 128M | 336M | 633M | 291M | 471M | 542M | 406M | 267M |
| Free Cash Flow | 84.6M | 88.6M | 104M | -127M | -493M | -251M | -278M | -136M | -175M | -170M |
| Ratios | ||||||||||
| ROE | 15.6% | 16.0% | 21.8% | 23.5% | 7.1% | 5.1% | 12.5% | 5.5% | -7.1% | -2.7% |
| ROA | 8.2% | 9.1% | 14.0% | 16.9% | 5.8% | 4.2% | 9.9% | 4.5% | -5.4% | -2.0% |
| Net Profit Margin | 13.5% | 12.6% | 22.7% | 29.0% | 20.3% | 16.9% | 27.5% | 18.9% | -46.0% | -17.1% |
| Debt to Equity | - | 0.21x | 0.16x | - | - | - | 0.01x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Changchun BCHT Biotechnology Co. A dividends
- Dividend yield
- 1.13%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 18, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 75.0M | 0.18 | - |
| 2024 | CNY 64.4M | 0.16 | 27.7% |
| 2023 | CNY 62.6M | 0.15 | 12.5% |
| 2022 | CNY 41.3M | 0.10 | 22.7% |
| 2021 | CNY 329K | 0.00 | 0.1% |
| 2020 | CNY 4.05M | 0.01 | 1.0% |
| 2019 | CNY 8.30M | 0.02 | 3.8% |
| 2018 | 18.5M | 0.05 | 14.4% |
| 2017 | 2.39M | 0.01 | 2.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Changchun BCHT Biotechnology Co. A
- Insiders 72.15%
- Institutions 0.60%
- Public & others 27.25%
- Shares outstanding 414M
- Free float 133M
Changchun BCHT Biotechnology Co. A company profile
- Company name
- Changchun BCHT Biotechnology Co. A
- Ticker
- 688276.SHG
- ISIN
- CNE100005XY6
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,252
- Fiscal year end
- December
- Address
- No. 1260 Huoju Road, Changchun, China
- Phone
- 86 40 0884 5777
- Website
- bchtpharm.com
About Changchun BCHT Biotechnology Co. A
Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. It offers therapeutic biological products; general cargo road transport; special cargo transport and import and export of goods and technology. The company's products Varicella vaccine, nasal spray flu vaccine, herpes zoster vaccine, liquid nasal spray flu vaccine. Changchun BCHT Biotechnology Co. Ltd. was founded in 2004 and is based in Changchun, China.
Changchun BCHT Biotechnology Co. A management
7- Mr. Chunlai JiangGM & Director · born 1973
- Mr. Zhaofeng MengChief Financial Officer · born 1964
- Mr. Zhe ZhangBoard Secretary · born 1976
- Mr. Dawei LiuDeputy General Manager · born 1972
- Ms. Wei WeiDeputy General Manager · born 1970
- Mr. Changlin ZhuSecretary of the Party Branch, Chairman of the Trade Union, & Chief Engineer of BaiKe Biotechnology · born 1969
- Zang YangExecutive Vice President of the Institute of Drug Research